Apoptosis
The number of cells in multicellular organism is tightly regulated. Not simply by controlling the rate of cell division, but also by controlling the rate of cell death. If cells are no longer needed, they commit suicide by activating an intracellular death program. This process is therefore called programmed cell death or apoptosis (from a Greek word meaning “falling off,” as leaves from a tree). The intrinsic apoptotic pathway occurs by the release of cytochrome c from mitochondria. The extrinsic apoptotic pathway is caused by the binding of death ligands, such as TNF (tumor necrosis factor), Fas, and TRAIL (TNF-related-apoptosis-inducing ligand), to their corresponding receptors. Although programmed cell death is involved in a number of key biological phenomena, aberrant apoptosis results in diverse human diseases [1].
The amount of apoptosis that occurs in developing and adult animal tissues is surprisingly large. In the developing vertebrate nervous system up to half or more of the nerve cells normally die soon after they are formed. In a healthy adult human, billions of cells die in the bone marrow and intestine every hour. Although this process seems remarkably wasteful -especially as the vast majority are perfectly healthy at the time they kill themselves- programmed cell death plays an important role during embryonic development, as hands and feet, for example, are sculpted by apoptosis: they start out as spadelike structures, and the individual digits separate only as the cells between them die. In other cases, cells die when the structure they form is no longer needed. When a tadpole changes into a frog, the cells in the tail die, and the tail, which is not needed in the frog, disappears. In many other cases, cell death helps regulate cell numbers. In the developing nervous system, for example, cell death adjusts the number of nerve cells to match the number of target cells that require innervation. In all these cases, the cells die by apoptosis as well[2].
[2] D.R. Williams et al. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew. Chem. Int. Ed. Engl. 2008, 47, 7466-7469.
[1] B. Alberts, A. Johnson, J. Lewis et al. Molecular Biology of the Cell. 4th edition. New York. Garland Science, 2002.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3995 | WT-161 | Potent,selective,and bioavailable HDAC6 inhibitor | Inquire | |
3114 | Vorinostat | HDAC inhibitor | €45.00 | |
3722 | Valemetostat | Inhibitor of Histone Lysine Methyltransferase EZH1/2 | €160.00 | |
1840 | UNC0646 | Inhibitor of G9a/GLP Histone Lysine Methyltransferase | €99.00 | |
1889 | UNC0638 | Inhibitor of G9a (EHMT2)/GLP (EHMT1) | €85.00 | |
1841 | UNC0631 | Inhibitor of G9a/GLP Histone Lysine Methyltransferase | €99.00 | |
2418 | UNC0379 | Substrate competitive inhibitor of the H4K20 HMTase SETD8 | €125.00 | |
1789 | UNC0224 | Inhibitor of G9a HMTase | €85.00 | |
2518 | UF 010 | Class I selective HDAC inhibitor that inhibits cancer cell proliferation | €60.00 | |
2893 | Tucidinostat | Orally bioavailable HDAC inhibitor (1, 2, 3, 10 Selective) | €95.00 | |
2004 | Tubastatin A hydrochloride | Potent and selective HDAC6 inhibitor | €95.00 | |
3691 | Tubacin | HDAC6 inhibitor | Inquire | |
2180 | TMP 195 | HDAC inhibitor (class IIA selective) | €110.00 | |
2996 | TH 34 | HDAC inhibitor (6, 8, 10 Selective) | €120.00 | |
2249 | Tenovin 6 | Small water soluble p53 activator and SIRT inhibitor | €105.00 | |
2008 | Tenovin 1 | Activates p53 through inhibition of SIRT 1 and 2 | €70.00 | |
5008 | Stem Cell RG-BIX inhibitor Set | Set of RG 108 and BIX 01294 HCl, inhibitors of DNMT and HMTase, respectively | €60.00 | |
2209 | Sodium butyrate | Noncompetitive inhibitor of multiple histone deacetylases (HDACs) | €50.00 | |
3908 | Sirtinol | Specific SIRT inhibitor | €90.00 | |
2968 | SIRT7 inhibitor 97491 | Inhibitor of SIRT7 | €135.00 | |
2453 | SirReal 2 | SIRT2 inhibitor with >1000 fold selectivity over SIRT1 and SIRT3 | €95.00 | |
1777 | SB 939 | HDAC inhibitor (1, 2, 4 Selective) | €95.00 | |
2495 | Santacruzamate A | Picomolar level HDAC2 inhibitor with little inhibition of HDAC4 and HDAC6 | €85.00 | |
2704 | Salermide | Potent inhibitor of SIRT1 and SIRT2 | €95.00 | |
2195 | RGFP 966 | HDAC3 specific inhibitor | €85.00 | |
1801 | Pyroxamide | HDAC1 Inhibitor | €90.00 | |
3695 | PF-06821497 | Inhibitor of Histone Lysine Methyltransferase EZH2 | €160.00 | |
1853 | PCI 34051 | HDAC8 Inhibitor | €90.00 | |
2530 | OTX 015 | Potent inhibitor of BRD2, BRD3, and BRD4 with clear anti-proliferative activity | €110.00 | |
3409 | NKL 22 | HDAC inhibitor | €80.00 |